Surface Oncology Inc

Surface Oncology — Investor Day (November 2019)

76 slides from Surface Oncology's investor day presentation, Nov 18, 2019

  1. Slide 1: Analyst and Investor R&D Day

    Analyst and Investor R&D Day November 18, 2019 Exhibit 99.2

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of ope

  3. Slide 3: Today's Agenda

    Today’s Agenda 8:15 – 8:35am Welcoming remarks and overview of corporate updates, strategy and vision Jeff Goater, President & CEO 8:35 – 9:30am Immunotherapy in Cancer: Immune Profiling, Mechanisms and Therapeutic Opportunities John Wherry, Ph.D. 9:30 - 9:45am Break 9:45 – 10:15am SRF617: A novel,

  4. Slide 4: Recent Corporate Highlights

    Recent Corporate Highlights Filed IND for SRF617 (CD39) SRF388 (IL-27) IND on track to be filed by end of this year New clinical candidate announced: SRF813, targeting CD112R Multiple poster presentations at SITC annual meeting Cash at end of Q3 2019: $111.8 million

  5. Slide 5: Break Through: mission and strong foundation

    BREAK THROUGH Financial resources and strategic partners provide STRONG FOUNDATION On a mission to dramatically IMPROVE CURE RATES FOR CANCER Proven leadership and UNIQUELY COLLABORATIVE SCIENTIFIC ADVISORS Deep biological expertise across the TUMOR MICROENVIRONMENT Focus on differentiated targets b

  6. Slide 6: Broad Approach Targeting the Immunosuppressive Tumor Microenvironment

    Block Suppressive Metabolites and Cytokines Activate Macrophages Deplete Regulatory T Cells Activate Natural Killer Cells Broad Approach Targeting the Immunosuppressive Tumor Microenvironment

  7. Slide 7: Characteristics of a Great Next-Generation I/O Target

    Characteristics of a Great Next-Generation I/O Target 1. Broad immune system engagement (innate & adaptive) 2. Biologic relevance and activity in the TME 3. Targeted translational approach

  8. Slide 8: Deep Collaboration With Renowned Advisors

    Deep Collaboration With Renowned Advisors Oncology Immunology Translational science Clinical development A break through philosophy Transformative impact for patients Collective learning SCIENTIFIC ADVISORY BOARD SURFACE TEAM Deep expertise in: Commitment to: Sasha Rudensky, PhD Carla Rothlin, PhD J

  9. Slide 9: SOSAS: Proprietary Computational Tool for Target ID

    Genome- & Disease-wide database analysis Strategic screening of new targets Target identification & validation SOSAS Workflow SOSAS: Proprietary Computational Tool for Target ID Surface Oncology Survival Analysis Suite Proprietary statistical methodology for new target discovery Leverages large data

  10. Slide 10: Broad Portfolio Targeting the Tumor Microenvironment

    Broad Portfolio Targeting the Tumor Microenvironment (1) (1) Novartis has option remaining on the program

  11. Slide 11: Overview of Ongoing Phase 1 Trial NZV930

    Overview of Ongoing Phase 1 Trial NZV930 Single Agent Dose Escalation NZV930 with PDR001 (Anti-PD-1) NZV930 with NIR178 (A2AR antagonist) NZV930, NIR178 & PDR001 (1) NSCLC, TNBC, Ovarian Cancer, MSS Colorectal, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma Enrollment spanning three combinat

  12. Slide 12: Overview of Lead, Wholly-Owned Product Programs

    Overview of Lead, Wholly-Owned Product Programs to be Reviewed Today SRF617 (CD39) Potent inhibitor of CD39 enzymatic activity Best target on the adenosine axis Dual mechanism: reduction of immuno-suppressive adenosine and increased levels of immunostimulatory extracellular ATP IND filed in November

  13. Slide 13: Overview of Lead, Wholly-Owned Product Programs

    Overview of Lead, Wholly-Owned Product Programs to be Reviewed Today SRF617 (CD39) Potent inhibitor of CD39 enzymatic activity Best target on the adenosine axis Dual mechanism: reduction of immuno-suppressive adenosine and increased levels of immunostimulatory extracellular ATP IND filed in November

  14. Slide 14: Overview of Lead, Wholly-Owned Product Programs

    Overview of Lead, Wholly-Owned Product Programs to be Reviewed Today SRF617 (CD39) Potent inhibitor of CD39 enzymatic activity Best target on the adenosine axis Dual mechanism: reduction of immuno-suppressive adenosine and increased levels of immunostimulatory extracellular ATP IND filed in November

  15. Slide 15: Emerging Trends in T cell Exhaustion and the Tumor Microenvironment

    Emerging Trends and Observations in T cell Exhaustion and the Tumor Microenvironment John Wherry, Ph.D. Professor, University of Pennsylvania Chair, Department of Systems Pharmacology and Translational Therapeutics Richard and Barbara Schiffrin President’s Distinguished Professor Director, Institute

  16. Slide 16: Immunotherapy in Cancer: Immune Profiling, Mechanisms and Therapeutic Opportunities

    Immunotherapy in Cancer: Immune Profiling, Mechanisms and Therapeutic Opportunities John Wherry, Ph.D.

  17. Slide 17: Break

    SURFACE ONCOLOGY. Break 9:30 — 9:45

  18. Slide 18: SRF617 (CD39): Engaging Innate and Adaptive Immunity

    SRF617 (CD39): Engaging Innate and Adaptive Immunity IND filed Planned Phase 1/1b clinical study to enroll patients with advanced solid tumors Initial clinical update in late 2020

  19. Slide 19: Characteristics of a Great Next Generation I/O Target

    Characteristics of a Great Next Generation I/O Target 1. Broad immune system engagement (innate & adaptive) 2. Biologic relevance and activity in the TME 3. Targeted translational approach

  20. Slide 20: SRF617 Engages Both the Innate and Adaptive Immune System

    SRF617 Engages Both the Innate and Adaptive Immune System ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) SRF617 SRF617 Reduces Plasma Adenosine Levels in Tumor-Bearing Mice

  21. Slide 21: SRF617 Mediated CD39 Blockade is Immunostimulatory

    21 ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) SRF617 SRF617 Mediated CD39 Blockade is Immunostimulatory SRF617 Stimulates Dendritic Cells, A Key Component of the Innate Immune System

  22. Slide 22: SRF617 Increases ATP Levels in Pancreatic Cancer Cultures

    22 Cell stress/ damage/ death (innate) ATP AMP Adenosine CD39 CD73 Innate and adaptive immune response SRF617 SRF617 Monotherapy or Combination with Gemcitabine Leads to Increased ATP Levels in Human Pancreatic Cancer Cultures * SRF617 Engages Both the Innate and Adaptive Immune System

  23. Slide 23: SRF617 Stimulates Key Components of the Innate Immune System

    SRF617 Stimulates Key Components of the Innate Immune System 23 Cell stress/ damage/ death (innate) ATP AMP Adenosine CD39 CD73 Innate and adaptive immune response SRF617 SRF617 Engages Both the Innate and Adaptive Immune System

  24. Slide 24: SRF617 Modulates Macrophage Trafficking and Tumor Infiltrate

    SRF617 Modulates Macrophage Trafficking and Tumor Infiltrate 24 Tumor macrophage infiltration MOLP8 Xenograft Model F4/80 IHC Cell stress/ damage/ death (innate) ATP AMP Adenosine CD39 CD73 Innate and adaptive immune response SRF617 SRF617 Engages Both the Innate and Adaptive Immune System

  25. Slide 25: Conclusion: A Highly Active Mechanism

    Conclusion: A Highly Active Mechanism 25 SRF617 Single Agent Activity in Xenograft MOLP8 In Vivo Model Murine Anti-CD39 Surrogate Cooperates with Anti-PD1 in CT26 Model, Increasing Cures Days on Study 10/18 CR 4/16 CR (Rechallenge)

  26. Slide 26: Measuring CD39 Target Occupancy and Enzymatic Inhibition

    Clear Approach to Measuring Both CD39 Target Occupancy and Enzymatic Inhibition by SRF617 in Circulation 26 Enzymatic Inhibition + SRF617 Target Occupancy % Target Occupancy % Enzymatic Inhibition

  27. Slide 27: SRF617 Inhibits CD39 Enzymatic Activity in TME of Treated Mice

    SRF617 Inhibits CD39 Enzymatic Activity in TME of Treated Mice – Key Assay for Human POC 27 Untreated 4 h 24 h 72 h + SRF617

  28. Slide 28: Key Phase 1 Bioassays to Assess Biologic POC

    Key Phase 1 Bioassays to Assess Biologic POC 28 PBMC Target Occupancy CD39 Enzymatic Activity by IHC Allows for Direct Measurement of CD39 Inhibition within the TME Binding of SRF617 to PBMCs is Highly Correlated to Enzymatic Inhibition

  29. Slide 29: Patterns of CD39 TME Expression Lead to Translational Hypotheses

    Patterns of CD39 TME Expression Lead to Translational Hypotheses in Tumor Types with High Clinical Need CD39 TIL expression CD39/CK Gastric CA CD39 CD39 stromal expression Pancreatic CA CD39/CK 29

  30. Slide 30: Stromal Expression – Targeting Chemo Combinations

    Stromal Expression – Targeting Chemo Combinations in Tumor Types with High Stromal Staining SRF617 + Doxorubicin In MOLP-8 SRF617 + Paclitaxel In NSCLC Xenograft Intense CD39 Stromal Staining in NSCLC Patient Sample Courtesy of Kurt Schalper, MD *p<0.05 30 * Dosing Ended

  31. Slide 31: CD39 Highly Expressed on TILs From Multiple Tumor Types

    TIL Expression - CD39 is Highly Expressed on TILs From Multiple Tumor Types and Associated with an Exhausted, Dysfunctional State % CD39 + PBMC CRC RCC PBMC – N=6 (Healthy Donors) CRC – N=4 RCC – N=5 31 CD39 Expression Increases in TILs CD39+ TILs are Exhausted and Dysfunctional CD39 Expression Duhe

  32. Slide 32: CD39 Expression Increases After PD-(L)1 Exposure

    TIL Expression – CD39 Expression Increases After PD-(L)1 Exposure *Surface data 5 individual PBMC donors -/+ Nivolumab at 10ug/ml 96-Hour incubation Cell types and %CD39 expression determined by flow *Clinical data, Corvus, SITC 2017 CD39 expression analysis from RCC and NSCLC screening biopsies Res

  33. Slide 33: Our Approach is to Identify and Revitalize These T Cells

    Our Approach is to Identify and Revitalize These T Cells Revitalize Identify Combo with A2A 10/18 CR 4/16 CR Combo with PD-1 33 Endometrial CA Gastric CA

  34. Slide 34: SRF617 Clinical Development Plan

    SRF617 Clinical Development Plan Phase 1/1b 34 Dose Escalation: Patients with advanced solid tumors Establish safe monotherapy dose (accelerated & 3+3 design) Establish safe combination therapy dose(s); anticipate staggered start after monotherapy Biopsy Expansion Cohort: Evaluate on-target tumor ti

  35. Slide 35: SRF617 – A Potent Inhibitor of the Adenosine Axis

    SRF617 – A Potent Inhibitor of the Adenosine Axis 1. Broad immune system engagement (innate & adaptive) 2. Biologic relevance and activity in the TME 3. Targeted translational approach Intrinsic properties of SRF617 Single-digit nanomolar monovalent affinity to human CD39 Potent inhibitor of hu/cyno

  36. Slide 36: SRF388 (IL-27): Potent Inhibition of an Immunosuppressive Cytokine

    SRF388 (IL-27): Potent Inhibition of an Immunosuppressive Cytokine With Potential Prognostic Biomarker IND expected by end of 2019 Biology supports highly targeted clinical strategy Initial clinical update in late 2020

  37. Slide 37: Five Key Takeaways from Today's Presentation

    Five Key Takeaways from Today’s Presentation The cytokine IL-27 is a regulator of immune suppression Strong translational hypotheses in RCC and HCC SRF388 is a novel, first-in-class anti-IL-27 antibody SRF388 was selected by leveraging a deep understanding of IL-27 and TME biology IND to be filed th

  38. Slide 38: IL-27 is a Cytokine Involved in Resolving T-cell Mediated Inflammation

    IL-27 is a Cytokine Involved in Resolving T-cell Mediated Inflammation IL-27 Receptor p28 Jak2 Jak1 STAT3 STAT1 Inflammatory Cytokines TNF⍺ +IL-27 Control EBI3 IL-27 Ligand Inhibitory Receptors on Immune Cells T N F ⍺ p g /m L Chihara et al, Nature 558, 2018 DeLong et al, Immunohorizons 3, 2019

  39. Slide 39: Pregnancy is Associated with Elevated IL-27

    Pregnancy, an Immune-tolerant State, is Associated with Elevated IL-27 Coulomb L’Hermine 2007 Detection of EBI3 in Serum Detection of Localized IL-27 Heterodimer in Placenta

  40. Slide 40: p28 is the Limiting Subunit for IL-27 Activity

    p28 is the Limiting Subunit for IL-27 Activity Serum derived EBI3 pairs with p28 to form bioactive IL-27 Only the p28-EBI3 heterodimer binds to IL-27RA with high affinity; biological activity of either subunit by itself has not been observed p28 EBI3 IL-27

  41. Slide 41: p28 is the Limiting Subunit for IL-27 Activity

    p28 is the Limiting Subunit for IL-27 Activity Media EBI3 Norm Serum Preg Serum EBI3 Norm Serum Preg Serum + p28 rIL-27 Serum derived EBI3 pairs with p28 to form bioactive IL-27 Only the p28-EBI3 heterodimer binds to IL-27RA with high affinity; biological activity of either subunit by itself has not

  42. Slide 42: EBI3 and p28 mRNA are Expressed in Tumors

    EBI3 and p28 mRNA are Expressed in Tumors HNSCC p28/EBI3 dual ISH with RNAscope EBI3 p28

  43. Slide 43: Levels of EBI3 are Elevated in Serum from Cancer Patients

    Levels of EBI3 are Elevated in Serum from Cancer Patients

  44. Slide 44: Levels of EBI3 are Elevated in Serum from Cancer Patients

    Levels of EBI3 are Elevated in Serum from Cancer Patients

  45. Slide 45: Gene Signature and Plasma EBI3 in RCC Predicts Poor Outcome

    Gene Signature and Plasma EBI3 Protein Levels in Renal Cell Carcinoma Patients Predicts Poor Outcome IL-27 T cell gene signature identified in a subset of RCC patients RCC U. Montreal Cohort- J. Stagg 187 RCC Plasma samples

  46. Slide 46: IL-27 Complex Components Associated with Poor Prognosis in RCC

    All Components of the IL-27 Complex are Associated with Poor Prognostic Outcomes in Renal Cell Carcinoma RCC (KIRC) Genome-wide Survival Statistics Genome-wide Hazard Ratios Better Worse

  47. Slide 47: IL-27 Induces PD-L1 Expression on RCC Tumor Cells

    IL-27 Induces the Expression of PD-L1 on Renal Cell Carcinoma Tumor Cells PD-L1 Surface Expression ACHN line (RCC) treated with IL-27 for 72 h

  48. Slide 48: Elevated mRNA Expression of p28 in Hepatocellular Carcinoma

    Elevated mRNA Expression of p28 in Hepatocellular Carcinoma P28 Expression (TCGA)

  49. Slide 49: Elevated mRNA Expression of p28 in Hepatocellular Carcinoma

    Elevated mRNA Expression of p28 in Hepatocellular Carcinoma Liver P28 Expression (TCGA)

  50. Slide 50: Vision Statement for SRF388

    Vision Statement for SRF388 SRF388, a first-in-class anti-IL-27 antibody, will substantially improve efficacy outcomes in patients with clear cell RCC and HCC who have high levels of circulating EBI3.

  51. Slide 51: Our Clinical Candidate: Anti-p28 Antibody SRF388

    Our Clinical Candidate: Anti-p28 Antibody SRF388 Single-digit picomolar affinity to p28 subunit of IL-27 Prevents IL-27 from engaging with IL-27R Blocks IL-27 mediated Stat1 phosphorylation Blocks IL-27 driven immunosuppression ü SRF388 IL-27 IL-27 Binding and Downstream Signaling ü ü ü

  52. Slide 52: SRF388 Restores Cytokine Production in Combination with αPD-1

    SRF388 Restores Cytokine Production in Combination with αPD-1 in Presence of rIL-27 in Healthy Donor PBMCs IFNγ, TNFα, IL-17 T cell PD1 Control ⍺PD-1 IL-27 + ⍺PD-1 Anti-PD-1 IL-27 Similar effects observed with IL-17 and TNFa

  53. Slide 53: SRF388 Restores Cytokine Production in Combination with αPD-1

    IL-27 SRF388 Restores Cytokine Production in Combination with αPD-1 in Presence of rIL-27 in Healthy Donor PBMCs IFNγ, TNFα, IL-17 T cell PD1 Control ⍺PD-1 IL-27 + ⍺PD-1 IL-27 + ⍺PD-1 + SRF388 Anti-PD-1 SRF388 Anti-PD-1 Similar effects observed with IL-17 and TNFa

  54. Slide 54: SRF388 Blocks IL-27 Induced Inhibitory Receptor Expression

    SRF388 Blocks IL-27 Induced Inhibitory Receptor Expression in Primary Immune Cells TIGIT PD-L1 TIM3 LAG3 IL-27R Similar effects with other inhibitory receptors on T cells & monocytes SRF388 IL-27 TIGIT PD-L1 TIM3 LAG3 Leukocyte

  55. Slide 55: SRF388 Inhibits Tumor Growth in Orthotopic HCC Model

    SRF388 Inhibits Tumor Growth in an Orthotopic Model of Hepatocellular Carcinoma SRF388 (50 mg/kg) was dosed IP BIW x 2 Starting day 5 Tumor growth was measured by bioluminescent imaging Hepa1-6-Luc Tumors

  56. Slide 56: SRF388 Clinical Development Plan

    Potential to explore combinations in RCC Single arm Phase 2 in RCC SRF388 Clinical Development Plan Renal Cell Cancer Monotherapy dose expansion (Mandatory pre & post-treatment biopsies) Hepatocellular Cancer Monotherapy safety Potential to explore combinations in HCC Monotherapy dose escalation in

  57. Slide 57: Translational Hypotheses with Patient Selection Potential

    EBI3 Immunoassay Immunohistochemistry Elevated expression of IL-27 pathway components Elevated levels of serum EBI3 Translational Hypotheses with Patient Selection Potential Tumor Biopsy Blood/ Serum Correlation with patient response mRNA Expression IL-27 gene expression signature

  58. Slide 58: Five Key Takeaways from Today's Presentation

    Five Key Takeaways from Today’s Presentation ü ü ü ü ü The cytokine IL-27 is a regulator of immune suppression Strong translational hypotheses in RCC and HCC SRF388 is a novel, first-in-class anti-IL-27 antibody SRF388 was selected by leveraging a deep understanding of IL-27 and TME biology IND to b

  59. Slide 59: SRF813 (CD112R): Unique Approach to New Checkpoint Inhibitor

    SRF813 (CD112R): Unique Approach to New Checkpoint Inhibitor Our first NK cell targeting program Potential to overcome PD-1 resistance and reactivate NK and T cell immunity

  60. Slide 60: Summary: An Immunotherapy With PD-1 Refractory Potential

    Summary: An Immunotherapy With PD-1 Refractory Potential T cell based immunotherapies have been transformative but resistance is emerging Currently there are no therapeutic strategies to overcome resistance to T cell checkpoint inhibitor blockade Emerging data highlights the potential of NK based th

  61. Slide 61: NK Cells are Critical for Optimal Antitumor Responses

    Dendritic cell NK Cells are Critical for Optimal Antitumor Responses Tumor cell NK cell Lytic granules MHC-deficient Inhibitory receptors Activating receptors Inhibitory ligands Stimulatory ligands + - Chemokines T Cell TCR IL-12 Antigen presentation

  62. Slide 62: NK Focused Immunotherapies Overcome T Cell-Associated Resistance

    NK Focused Immunotherapies Provide a Strategy to Overcome T Cell-Associated Tumor Immune Resistance Freeman, et al Cell Reports, 28, 2019 Genes that when depleted are associated with increased sensitivity to NK mediated killing Tumor cell NK cell MHC I low NK sensitivity Genes that when depleted pro

  63. Slide 63: CD112R is an Inhibitory Receptor Expressed on NK and T Cells

    NK cell CD112R is an Inhibitory Receptor Expressed on NK and T Cells CD112R expression increased on activated NK/T cells anti-CD3 stimulation NK Cells Tumor cell CD112 CD112R CD226 CD112 CD16

  64. Slide 64: CD112R is an Inhibitory Receptor Expressed on NK and T Cells

    NK cell CD112R is an Inhibitory Receptor Expressed on NK and T Cells CD112R expression increased on activated NK/T cells CD8 T Cells NK Cells Tumor cell CD112 CD112R CD226 CD112 CD16 TCR T Cell CD226 CD112R anti-CD3 stimulation

  65. Slide 65: CD112R is an Inhibitory Receptor Expressed on NK and T Cells

    NK cell CD112R is an Inhibitory Receptor Expressed on NK and T Cells Tumor cell CD112 TCR T Cell CD112R CD226 CD112 CD16 CD226 CD112R Upregulated on CT26 tumor infiltrating NK/T cells

  66. Slide 66: SRF813 Promotes NK Cell Activation

    The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation NK cell Tumor cell CD112 CD16 CD112R CD226 PBMC-NK activation assay K562 Cells NK degranulation assay Raji.CD112 Cells

  67. Slide 67: SRF813 Promotes NK Cell Activation

    The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation PBMC-NK activation assay NK degranulation assay Raji.CD112 Cells K562 Cells NK cell Tumor cell CD112 CD16 IgG4 Abs CD112R CD226

  68. Slide 68: SRF813 Promotes NK Cell Activation

    The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation PBMC-NK activation assay NK degranulation assay Raji.CD112 Cells K562 Cells NK cell Tumor cell CD112 Ab-A IgG1 CD16 CD112R CD226

  69. Slide 69: SRF813 Promotes NK Cell Activation

    The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation NK cell Tumor cell CD112 PBMC-NK activation assay NK degranulation assay Raji.CD112 Cells K562 Cells SRF813 + + activation + + + CD16 CD112R CD226

  70. Slide 70: CD112R is a Negative Regulator of T Cell Activation

    CD112R is a Negative Regulator of T Cell Activation T cell Tumor cell IL-2 CD112 CD112R TCR CD112R overexpression abrogates T cell activation SRF813 enhances T cell activation SRF813

  71. Slide 71: CD112R Antibody Delays Tumor Growth and Promotes Immunological Memory

    CD112R Antibody Delays Tumor Growth and Promotes Immunological Memory Anti-muCD112R 25 mg/kg, starting day 4 (BIW x 3) Anti-tumor activity as a single agent Naive Re-challenged Tumor free re-challenged display immunological memory Activity is NK and T cell dependent Isotype anti-muCD112R

  72. Slide 72: SRF813 Activity is Dependent on CD16 Engagement

    SRF813 Activity is Dependent on CD16 Engagement In vitro NK cell activity assay K562 Cells CD16 CD112R Distinct epitope and isotype important for functional activity Competitor Model for SRF813 binding CD112 SRF813 + Tumor cell NK Cell CD226 + - CT26 syngeneic tumor model muIgG1 = low affinity bindi

  73. Slide 73: SRF813 – an Antibody Targeting CD112R

    SRF813 – an Antibody Targeting CD112R High affinity, fully human IgG1 antibody against human CD112R Binds distinct epitope and blocks CD112-CD112R interaction Enhances NK/T cell activation and cytotoxicity CD112R blockade promotes antitumor immunity in mice SRF813 represents a new therapeutic approa

  74. Slide 74: Q&A

    JURFALCE ONCOLOGY. Q&A 11:00 am — 12:00 pm

  75. Slide 75: Final Remarks from Jeff Goater, President & CEO

    Final Remarks from Jeff Goater, President & CEO 12:05 PM

  76. Slide 76: Thank You

    Thank You 4

Surface Oncology — Investor Day (November 2019) on 6ix